Clinigen has appointed Greg Skalicky as Group Chief Executive Officer, effective July 20, 2026, succeeding Dr. Varun Sethi, who has served as Acting CEO since September 2025. The global pharmaceutical services company said the leadership change comes as it prepares for its next phase of growth focused on accelerating access to critical medicines worldwide.
Skalicky brings more than 30 years of leadership experience spanning clinical and commercial roles across the pharmaceutical, biotechnology, and healthcare sectors. He joins Clinigen following a distinguished career leading large-scale organizations and building innovative partnership models. Most recently, he served as President of Eversana, where he designed and implemented what the company describes as the industry’s first fully integrated commercialization model. His earlier senior roles at Syneos Health (formerly inVentiv Health) and PharmaNet included managing major global client relationships with leading pharmaceutical companies.
As Group CEO, Skalicky will oversee Clinigen’s efforts to deepen its role as a trusted partner to pharma and biotech companies across clinical trial services, strategic staffing, and global compassionate use programs. Chairman Paul Carter said Skalicky’s extensive experience in commercialization, patient access, and pharmaceutical services makes him well positioned to advance Clinigen’s ambition to offer clients a fully integrated partner across the pharmaceutical lifecycle. He also thanked Sethi for his “outstanding leadership” as Acting CEO.
Skalicky said he is honored to join Clinigen at “an exciting time” in its evolution, praising the company’s reputation for solving complex access and supply challenges. He added that he looks forward to working with Clinigen’s global team to accelerate growth, enhance client value, and expand access to critical medicines for patients worldwide.